Provided by Tiger Trade Technology Pte. Ltd.

Corbus Pharmaceuticals

5.42
+0.15002.85%
Volume:568.87K
Turnover:3.08M
Market Cap:104.83M
PE:-0.89
High:5.61
Open:5.25
Low:5.17
Close:5.27
52wk High:20.56
52wk Low:5.13
Shares:19.34M
Float Shares:13.25M
Volume Ratio:0.62
T/O Rate:4.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.0889
EPS(LYR):-5.9000
ROE:-95.58%
ROA:-53.00%
PB:1.03
PE(LYR):-0.92

Loading ...

U.S. RESEARCH ROUNDUP-Coca-Cola Co, Mondelez, Zeta Global Holdings

Reuters
·
Apr 29

Corbus Pharmaceuticals Holdings Inc : Guggenheim Initiates Coverage With Buy Rating; Target Price $45

THOMSON REUTERS
·
Apr 29

Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
Apr 29

Corbus Pharmaceuticals initiated with a Buy at Guggenheim

TIPRANKS
·
Apr 29

Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
Apr 25

Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Apr 23

Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701

GlobeNewswire
·
Apr 22

Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
Apr 22

Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Apr 17

Corbus Pharmaceuticals Updates Executive Employment Agreements and Protections

TIPRANKS
·
Apr 17

Corbus CEO Cohen base salary rises to $673,625 under amended employment agreement

Reuters
·
Apr 17

Corbus Pharmaceuticals announces last person enrolled in CANYON-1 trial

TIPRANKS
·
Apr 14

Corbus enrolls last patient in Phase 1b CANYON-1 obesity trial of CRB-913

Reuters
·
Apr 14

Corbus Pharmaceuticals Holdings Inc - Canyon-1 Study on Track for Completion in Summer 2026

THOMSON REUTERS
·
Apr 14

Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Apr 14